TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23328090

Group type: EXPERIMENTAL
Intervention: lersivirine 500 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 193

Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: lersivirine 500 mg
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg
Number of subjects: 193

Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: lersivirine
Number of subjects: 193
Study: 22268268

Group type: EXPERIMENTAL
Intervention: Speculum retention technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional transfer technique
Number of subjects: 100
Study: 19057955

Group type: EXPERIMENTAL
Intervention: Laparoscopic colon resection (LCR)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Included patients (group 1)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Nonincluded patients (group 4)
Number of subjects: 391
Study: 16435117

Group type: EXPERIMENTAL
Intervention: Fixed pharmaceutical budgets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open-ended budgets
Number of subjects: 0
Study: 12742982

Group type: EXPERIMENTAL
Intervention: IL-7 levels in patients with unstable angina
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IL-7 levels in patients with stable angina
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IL-7 expression in peripheral blood mononuclear cells
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aspirin (160 mg qd for 7 days)
Number of subjects: 80
Study: 10823263

Group type: EXPERIMENTAL
Intervention: Pravastatin (adequate LDL-C reduction)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pravastatin (inadequate LDL-C reduction)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (with LDL-C reduction)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (without LDL-C reduction)
Number of subjects: 57
Study: 8888744

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TF) at doses of 25 or 50 micrograms/h
Number of subjects: 10
Study: 1740198

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracervical insemination
Number of subjects: 0
Study: 6325864

Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell-wall skeleton (N-CWS) treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no N-CWS treatment)
Number of subjects: 190
Study: 31500849

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5‐min inflation and 5‐min deflation of an automated cuff device)
Number of subjects: 5401

Group type: COMPARATOR
Intervention: Standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only)
Number of subjects: 5401
Study: 28230557

Group type: EXPERIMENTAL
Intervention: Conventional Dresden protocol (3 mW/cm for 30 min, dose 5.4 J/cm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Accelerated protocol (30 mW/cm for 3 min 40 s, dose 6.6 J/cm)
Number of subjects: 25
Study: 26984444

Group type: EXPERIMENTAL
Intervention: Retropubic midurethral tape (MUT) procedure
Number of subjects: 100
Study: 24434073

Group type: EXPERIMENTAL
Intervention: Coming Out Proud (COP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 100
Study: 23700932

Group type: EXPERIMENTAL
Intervention: Methyldioxotetrahydropyrimidine sulfonisonicotinoyl hydrazide (MSH) at a daily dose of 800-1200 mg for 2-5 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MSH on drug susceptible MBT
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MSH on drug resistant MBT (isoniazid MIC of 1 mcg/ml)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MSH on isoniazid resistant MBT at 10 mcg/ml
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MSH
Number of subjects: 102
Study: 20048237

Group type: EXPERIMENTAL
Intervention: Home visitation program
Number of subjects: 643
Study: 17394176

Group type: EXPERIMENTAL
Intervention: Brief Pain Management Program (BPM)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 402
Study: 16121879

Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% intraperitoneal spray
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% intraperitoneal spray mixed with 200 mg ketoprofen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% intraperitoneal spray and intravenous 200 mg ketoprofen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 mg ketoprofen intravenously
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 11876691

Group type: EXPERIMENTAL
Intervention: Low-dose azathioprine (< 2 mg/kg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 113
Study: 10438404

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (100 mg x 2/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral micronized progesterone (200 mg x 4/day)
Number of subjects: 64
Study: 8566939

Group type: EXPERIMENTAL
Intervention: Volunteers searching for RCTs
Number of subjects: 3
Study: 1637021

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 500 mg twice daily for 20 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Doxycycline, 100 mg three times daily for 20 days
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 123

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 123
Study: 6383111

Group type: EXPERIMENTAL
Intervention: Ergometrine 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syntocinon 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 31498136

Group type: EXPERIMENTAL
Intervention: Intervention rehabilitation unit (IU) with naturalistic lighting (artificial sunlight spectrum)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control rehabilitation unit (CU) with standard indoor lighting
Number of subjects: 90
Study: 29305451

Group type: EXPERIMENTAL
Intervention: Meniscal allograft transplantation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Personalized physiotherapy
Number of subjects: 36
Study: 25844756

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Lurasidone 80-120 mg
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 485
Study: 23228988

Group type: COMPARATOR
Intervention: ACNU alone
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: ACNU + PCZ
Number of subjects: 310

Group type: COMPARATOR
Intervention: ACNU alone (GBM subgroup)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: ACNU + PCZ (GBM subgroup)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 310
Study: 21515398

Group type: EXPERIMENTAL
Intervention: Beta-glucan (3 g/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19112336

Group type: EXPERIMENTAL
Intervention: Limaprost (15 microg/d)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Etodolac (400 mg/d)
Number of subjects: 79
Study: 16014819

Group type: EXPERIMENTAL
Intervention: Behavioral and nutrition treatment (nutrition counseling and child behavioral management training for parents)
Number of subjects: 1
Study: 15574145

Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study: 11789748

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement
Number of subjects: 72
Study: 9384464

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 2 ng kg(‐1) min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 4 ng kg(‐1) min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 8 ng kg(‐1) min(‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1314337

Group type: EXPERIMENTAL
Intervention: Methoxamine (intravenous administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine (NE, intravenous administration)
Number of subjects: 0
Study: 3908131

Group type: EXPERIMENTAL
Intervention: iodopropylidene glycerol (IPG-Organidin), two tablets four times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: iodopropylidene glycerol (IPG-Organidin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 15
Study: 30620140

Group type: EXPERIMENTAL
Intervention: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate (10 mg/ml) and nepafenac (1 mg/ml)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No preoperative anti-inflammatory treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate and nepafenac
Number of subjects: 103
Study: 29652778

Group type: EXPERIMENTAL
Intervention: Neck Stabilization Exercises (NSE)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) and Neck Stabilization Exercises (NSE)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Interferential Current (IFC) and Neck Stabilization Exercises (NSE)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (NSE only)
Number of subjects: 81
Study: 27171319

Group type: EXPERIMENTAL
Intervention: Pelvic floor health information workshop (2-hour duration)
Number of subjects: 40
Study: 25064627

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (T&A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 80
Study: 22971487

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally once daily
Number of subjects: 586

Group type: COMPARATOR
Intervention: Naproxen 500 mg orally twice daily
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 586

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 586
Study: 20200972

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19087678

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus continuous renal replacement therapy (CRRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study: 16238122

Group type: EXPERIMENTAL
Intervention: 0.5 g of xanthan gum with test meal (ham sandwich - 90 kcal)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo with test meal (ham sandwich - 90 kcal)
Number of subjects: 21
Study: 12236643

Group type: EXPERIMENTAL
Intervention: Bevel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chamfer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Butt joint
Number of subjects: 45
Study: 9952140

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Air therapy (control)
Number of subjects: 100
Study: 7749825

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 60 IU/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 200 IU/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 400 IU/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 800 IU/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 1200 IU/d
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1971660

Group type: EXPERIMENTAL
Intervention: Cholestyramine or Pravastatin treatment
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with ischaemic heart disease (n=48)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (matched for age and sex)
Number of subjects: 47
Study: 393078

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30048324

Group type: EXPERIMENTAL
Intervention: Low-dose contrast enhanced CT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard CT
Number of subjects: 60
Study: 30523055

Group type: EXPERIMENTAL
Intervention: Daunorubicin, mitoxantrone, or idarubicin in addition to standard-dose cytarabine and etoposide for induction chemotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Standard-dose cytarabine or high-dose cytarabine induction, both with daunorubicin and etoposide
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: HLA-identical related donor availability
Number of subjects: 188
Study: 28940815

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, pantoprazole 40 mg twice daily for 10 days)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Sequential therapy (amoxicillin 1000 mg with pantoprazole 40 mg twice daily for 5 days, followed by clarithromycin 500 mg with metronidazole 500 mg and pantoprazole 40 mg twice daily for 5 days)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Concomitant therapy in clarithromycin-resistant strains
Number of subjects: 478

Group type: COMPARATOR
Intervention: Sequential therapy in clarithromycin-resistant strains
Number of subjects: 478
Study: 26114582

Group type: EXPERIMENTAL
Intervention: Touch-screen version of health status questionnaires (HSQs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper version of health status questionnaires (HSQs)
Number of subjects: 20
Study: 22868243

Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m² twice daily on days 1‐14 (Arm A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Capecitabine 1000 mg/m² twice daily on days 1‐14, oxaliplatin 100 mg/m² on day 1 initially, 130 mg/m² for subsequent cycles (Arm B)
Number of subjects: 80
Study: 20955744

Group type: EXPERIMENTAL
Intervention: Short-term counselling
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intensive counselling
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cognitive restraint
Number of subjects: 49
Study: 19053049

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day) with a 1,400 Kcal/day diet plus vitamin E (800 IU) daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diet plus vitamin E (800 IU) daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight loss >= 5%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight loss >= 9%
Number of subjects: 50
Study: 17041248

Group type: EXPERIMENTAL
Intervention: COPE program (Creating Opportunities for Parent Empowerment)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 143
Study: 15069395

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 238
Study: 11157603

Group type: EXPERIMENTAL
Intervention: Moxifloxacin, 400 mg/d for 10 days
Number of subjects: 411

Group type: COMPARATOR
Intervention: Amoxicillin, 1,000 mg tid for 10 days
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 411

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 411
Study: 9593156

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g/8 h)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g/8 h) plus Gentamicin (4 mg/kg daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cefuroxime plus Gentamicin
Number of subjects: 79
Study: 7921936

Group type: EXPERIMENTAL
Intervention: Modified Needle Suspension (MNS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vagina/Obturator Shelf (VOS)
Number of subjects: 50
Study: 2848900

Group type: EXPERIMENTAL
Intervention: 400 mg of oral acyclovir, twice daily for one year
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo, twice daily for one year
Number of subjects: 33
Study: 29636004

Group type: EXPERIMENTAL
Intervention: Central venous administration of sufentanil (group CV)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Peripheral venous administration of sufentanil (group PV)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (CV and PV)
Number of subjects: 102
Study: 28543352

Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26628268

Group type: EXPERIMENTAL
Intervention: Internet-delivered six-lesson 10-week cognitive behavioural therapy (iCBT) intervention for PTSD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 72
Study: 23987791

Group type: EXPERIMENTAL
Intervention: Aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiemetic therapy alone
Number of subjects: 0
Study: 18771232

Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering therapy (HbA1c < 6%) in ACCORD trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering therapy (HbA1c ≤ 6.5%, modified release gliclazide as main treatment) in ADVANCE trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering therapy in VA-Diabetes trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard glucose control in ACCORD, ADVANCE, and VA-Diabetes trials
Number of subjects: 0
Study: 15705991

Group type: EXPERIMENTAL
Intervention: Inhaled colistin (75 mg in 4 mL saline solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled colistin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12851547

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no vitamin E)
Number of subjects: 66
Study: 10564839

Group type: EXPERIMENTAL
Intervention: Aerosolized ABT-431 (5 mg); C(max) was 13.3±0.9 ng/ml and AUC(0-24) was 33.2±10.6 h ng/ml in dogs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral inhalation of ABT-431 (dosage levels between 3.3 and 13.2 mg); demonstrated rapid absorption and dose-dependent increase in AUC.
Number of subjects: 0
Study: 8708961

Group type: EXPERIMENTAL
Intervention: Single instrumentation (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Multiple instrumentations (Group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 15
Study: 1746653

Group type: EXPERIMENTAL
Intervention: AIDS education, HIV antibody test, and test results
Number of subjects: 186

Group type: COMPARATOR
Intervention: AIDS education alone
Number of subjects: 186
Study: 6269770

Group type: COMPARATOR
Intervention: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, and Adriamycin (VOCA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, Adriamycin (VOCA) plus low-dose (40 mg/m2) cisplatin (VOCAP)
Number of subjects: 62
Study: 30032394

Group type: EXPERIMENTAL
Intervention: SST (Social Skills Training)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: SST-PTI (Social Skills Training with Parent and Teacher Involvement)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: SST
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: SST-PTI
Number of subjects: 122
Study: 27294349

Group type: EXPERIMENTAL
Intervention: Grapefruit Juice (GFJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pomegranate Juice (PJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 12
Study: 25918277

Group type: EXPERIMENTAL
Intervention: PediQUEST Memorial Symptom Assessment Scale (PQ‐MSAS) administered 920 times
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PediQUEST Memorial Symptom Assessment Scale (PQ‐MSAS) in the last 12 weeks of life
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mild cancer‐directed therapy in the final 12 weeks of life
Number of subjects: 104
Study: 23602942

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program, 12 sessions
Number of subjects: 145
Study: 21347803

Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg once daily for 52 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 19081190

Group type: EXPERIMENTAL
Intervention: Topical high concentration (10%) capsaicin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of three GCH1 SNPs
Number of subjects: 39
Study: 16806618

Group type: EXPERIMENTAL
Intervention: Low back pain group (N=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy subjects (N=24)
Number of subjects: 50
Study: 15242361

Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vardenafil (all doses)
Number of subjects: 283
Study: 11224865

Group type: EXPERIMENTAL
Intervention: Percutaneous intradiscal radiofrequency thermocoagulation (90 seconds, 70 C lesion)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (same procedure without radiofrequency current)
Number of subjects: 28
Study: 9412546

Group type: EXPERIMENTAL
Intervention: Immunostimulant (OM-85 BV)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 8510708

Group type: EXPERIMENTAL
Intervention: Inhaled heparin (1000 U per kilogram)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3548314

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone plus Estrace 2 mg b.i.d. sublingually for 3 days before and on the day of chemotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Aminoglutethimide and hydrocortisone plus cyclic chemotherapy (control group)
Number of subjects: 39
Study: 31748427

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiroxostat
Number of subjects: 0